Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

Press Release

  • 08 October 2024
    Pharma Peers Unite to Build DNA-Encoded Libraries
    Finding tools and hits for targets in drug discovery can feel like hunting for four leaf clovers in a blizzard. And researcher Sylvie Sakata was close to giving up on one discovery tool, DNA-encoded libraries, when a new consortium started to fall into place. Now this technology is garnering more interest for its potential to discover new molecular compounds, known as “hits,” to exponentially impact the early research efforts that can lead to potential new medicines.
  • 28 August 2024
    Infographic | HitGen FY2024H1 Report
    Infographic | HitGen FY2024H1 Report
  • 22 August 2024
    Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program
    CHENGDU, China, August 22, 2024 – Bridge Biotherapeutics ("Bridge", KQ288330), a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc. ("HitGen", SSE: 688222.SH), a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen’s DNA-encoded library (DEL), aiming to further develop the novel hits as promising drug candidates for cancer.
  • 24 April 2024
    Infographic | HitGen FY2023&2024Q1 Report
    Infographic | HitGen FY2023&2024Q1 Report
  • 08 April 2024
    Vernalis announces a drug discovery collaboration with C4X Discovery in inflammatory disease
    Vernalis (R&D) Limited (“Vernalis”), a wholly owned subsidiary of HitGen Inc., and C4X Discovery (“C4XD”) are pleased to announce a collaboration to identify modulators of an undisclosed high-value target involved in inflammatory disease.
  • 26 March 2024
    HitGen Partners with LabCentral / BioLabs / MBC BioLabs to Accelerate Biotechnology Discovery
    [San Francisco, CA – March 25, 2024] – LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership-based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, announced a partnership with HitGen, a global leader in the design, synthesis, and screening of DNA-encoded chemical libraries (DELs).
  • 21 February 2024
    Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology
    Hox Therapeutics Ltd (“Hox”) a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.
  • 13 November 2023
    Get ready for the end-of-year sale! Discover the future of drug discovery with OpenDEL™ and save 20% off!
  • 27 October 2023
    Infographic | HitGen FY2023 Q3 Report
  • 19 October 2023
    Venture forces invest millions in new type of treatment for particularly aggressive form of cancer
    A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made an investment in the Danish biotech company Dania Therapeutics (Dania Tx).

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
验证码
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information